BiomX Inc. (NYSEAMERICAN:PHGE) Short Interest Down 17.5% in December

BiomX Inc. (NYSEAMERICAN:PHGE) was the recipient of a significant decline in short interest during the month of December. As of December 31st, there was short interest totaling 64,583 shares, a decline of 17.5% from the December 15th total of 78,258 shares. Based on an average trading volume of 64,617 shares, the short-interest ratio is presently 1.0 days. Approximately 4.4% of the shares of the company are sold short. Approximately 4.4% of the shares of the company are sold short. Based on an average trading volume of 64,617 shares, the short-interest ratio is presently 1.0 days.

Analyst Upgrades and Downgrades

Separately, HC Wainwright raised their price objective on BiomX to $26.00 and gave the stock a “buy” rating in a report on Tuesday, November 25th. One research analyst has rated the stock with a Buy rating, According to data from MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus target price of $26.00.

BiomX Trading Up 2.6%

Shares of PHGE opened at $2.75 on Wednesday. The company’s 50 day simple moving average is $3.34 and its 200-day simple moving average is $7.36. BiomX has a 12-month low of $1.50 and a 12-month high of $22.06. The firm has a market cap of $4.21 million, a PE ratio of -0.11 and a beta of 1.60.

About BiomX

BiomX Inc is a clinical-stage biotechnology company that specializes in developing precision bacteriophage therapies to target pathogenic bacteria in the human microbiome. By harnessing the natural ability of bacteriophages to selectively infect and lyse harmful bacterial strains, BiomX aims to restore microbial balance without disrupting beneficial commensal organisms. The company’s platform integrates phage discovery, formulation and genetic engineering to create tailored phage cocktails for a range of microbiome-associated diseases.

The company’s pipeline includes lead clinical candidates for gastrointestinal disorders such as pouchitis and ulcerative colitis, as well as programs addressing dermatological indications including acne and atopic dermatitis.